Brain Metastases and Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: a Systematic Review and Meta-analysis

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2022 Jun 1

PMID 35648238

Authors

Haizhu Chen

Yu Feng

Yu Zhou

Yunxia Tao

Le Tang

Yuankai Shi

Affiliations

Soon will be listed here.

Abstract

Background: The use of immune checkpoint inhibitors (ICIs) for brain metastases (BMs) from non-small cell lung cancer (NSCLC) remains debatable. This study aimed to explore the efficacy of ICIs for NSCLC with BMs. We also evaluated the effect of BMs on outcomes of ICIs.

Methods: A systematic search of PubMed, Embase, Web of Science, and Cochrane databases was conducted to identify studies where the efficacy of ICIs against BMs from NSCLC, or the association between BMs and outcomes of ICIs were evaluated. Outcomes included intracranial objective response rate (icORR), intracranial disease control rate (icDCR), systemic ORR and DCR.

Results: Overall, 33 studies were included in this meta-analysis. The pooled icORR was 13% (95%CI 6-23%) and icDCR was 50% (95%CI 40-63%) for programmed cell death-ligand 1 (PD-L1) unselected patients with any BMs. For active BMs, pooled icORR was 15% (95%CI 6-28%) and icDCR was 47% (95% CI 36-57%). For PD-L1 ≥ 50% patients with any BMs, pooled icORR and icDCR were 68% (95%CI 57-80%) and 82% (95%CI 73-92%), respectively. Additionally, pooled systemic ORR and DCR for any BMs were 22% (95%CI 15-30%) and 41% (95%CI 18-67%), respectively. Patients with BMs had inferior progression-free survival (HR 1.19, 95%CI 1.07-1.33, P = 0.0016) and overall survival (HR 1.14, 95%CI 1.03-1.25, P = 0.011) when applying ICIs compared to those without BMs. However, no significant difference in systemic ORR between patients with and without BMs was observed (OR 0.94, 95%CI 0.72-1.20, P = 0.629).

Conclusion: ICIs may be clinically active in NSCLC patients with BMs. More effective treatments for BMs from NSCLC are needed.

Citing Articles

A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer.

Lu R, Wang Z, Tian W, Shi W, Chu X, Zhou R Sci Rep. 2025; 15(1):7036.

PMID: 40016281 PMC: 11868486. DOI: 10.1038/s41598-025-91863-7.

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study.

Fang W, Peng X, Zhou Q J Cardiothorac Surg. 2024; 19(1):478.

PMID: 39090722 PMC: 11295867. DOI: 10.1186/s13019-024-02975-6.

Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials.

Guo T, Zhou Y, Liang F, Wang Z, Bourbonne V, Kasmann L Cancer Commun (Lond). 2023; 44(2):278-281.

PMID: 38145967 PMC: 10876190. DOI: 10.1002/cac2.12512.

A case of discordant histology and expression of programmed death ligand 1 between primary tumor and brain metastases in adenosquamous carcinoma of the lung.

Takagi H, Muto S, Enta A, Fukuhara M, Asano S, Shio Y Thorac Cancer. 2023; 14(26):2707-2711.

PMID: 37545057 PMC: 10493479. DOI: 10.1111/1759-7714.15061.

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors.

Alimonti P, Gonzalez Castro L Antibodies (Basel). 2023; 12(2).

PMID: 37092448 PMC: 10123751. DOI: 10.3390/antib12020027.

References

Kelly K, Bunn Jr P . Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?. Lung Cancer. 1998; 20(2):85-91. DOI: 10.1016/s0169-5002(98)00020-8. View

Skribek M, Rounis K, Makrakis D, Agelaki S, Mavroudis D, De Petris L . Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting. Cancers (Basel). 2020; 12(12). PMC: 7764720. DOI: 10.3390/cancers12123707. View

Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J . Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2020; 9(3):305-314. DOI: 10.1016/S2213-2600(20)30365-9. View

Alessi J, Ricciuti B, Jimenez-Aguilar E, Hong F, Wei Z, Nishino M . Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020; 8(2). PMC: 7406027. DOI: 10.1136/jitc-2020-001007. View

Mountzios G, De Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G . Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2020; 22(2):e180-e192. DOI: 10.1016/j.cllc.2020.09.017. View

Mansfield A, Aubry M, Moser J, Harrington S, Dronca R, Park S . Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016; 27(10):1953-8. PMC: 5035793. DOI: 10.1093/annonc/mdw289. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S . Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020; 15(10):1636-1646. DOI: 10.1016/j.jtho.2020.07.014. View

Hu H, Xu Z, Zhu Q, Liu X, Jiang S, Zheng J . Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis. Front Immunol. 2021; 12:669398. PMC: 8316922. DOI: 10.3389/fimmu.2021.669398. View

10.

Crino L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E . Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019; 129:35-40. DOI: 10.1016/j.lungcan.2018.12.025. View

11.

Juergens R, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume M . Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol. 2019; 25(6):384-392. PMC: 6291291. DOI: 10.3747/co.25.4287. View

12.

Gibney G, Weiner L, Atkins M . Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016; 17(12):e542-e551. PMC: 5702534. DOI: 10.1016/S1470-2045(16)30406-5. View

13.

Tamiya M, Tamiya A, Inoue T, Kimura M, Kunimasa K, Nakahama K . Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. PLoS One. 2018; 13(2):e0192227. PMC: 5823394. DOI: 10.1371/journal.pone.0192227. View

14.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

15.

Lang D, Horner A, Brehm E, Akbari K, Hergan B, Langer K . Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study. Lung Cancer. 2019; 134:59-65. DOI: 10.1016/j.lungcan.2019.05.033. View

16.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

17.

Metro G, Banna G, Signorelli D, Gili A, Galetta D, Galli G . Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%. J Immunother. 2020; 43(9):299-306. DOI: 10.1097/CJI.0000000000000340. View

18.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

19.

de Alencar V, Camandaroba M, Pirolli R, Fogassa C, Cordeiro de Lima V . Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis-the META-L-BRAIN Study. J Thorac Oncol. 2021; 16(8):1379-1391. DOI: 10.1016/j.jtho.2021.04.014. View

20.

Ma S, Tang X, Long L, Bai X, Zhou J, Duan Z . Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. Oncoimmunology. 2021; 10(1):1909296. PMC: 8078693. DOI: 10.1080/2162402X.2021.1909296. View